The two big bullish catalysts for biotech stocks

The SPDR S&P Biotech ETF (XBI) has surged 49 percent in 2017 to its highest level in more than two years, but some say the move isn't over just yet.

Erin Gibbs, a portfolio manager with S&P Global, points out that "the average stock in the XBI is trading at 21 percent below its [average] analyst target price. The average stock is rated a buy."

Meanwhile, biotech valuations "are just starting to recover," she wrote to CNBC on Friday, while the forward price-earnings ratio for the S&P 500 as a whole "has remained at the top of a 3 year range."

In other words, biotech valuations may have more upside than broad-market valuations.

Of course, valuations are low for a reason. Gibbs also pointed out that "biotech is expected to have earnings contract -3.3 percent in 2017 and then recover to 6.6 percent [earnings per share] growth in 2018."

"Not exactly stellar growth, and well below the broader market. But at least the stocks are relatively cheaper even with the recent appreciation," she added.

All in all, Gibbs says that thanks to low valuations and high price targets, biotech stocks have "room to appreciate further," even if they are not "a strong buy."

BK Asset Management's Boris Schlossberg, however, is quite cautious on the space in the short term.

"At this point, some pause is kind of due," he said Friday on CNBC's "Trading Nation." The XBI chart is "coming up against a very long-term resistance" at the ETF's mid-2015 intraday high of $91.11, Schlossberg said.

On Friday, the XBI slipped slightly to close at $88.32.


Trades to Watch

Trader Bios


Trading Nation is a multimedia financial news program that shows investors and traders how to use the news of the day to their advantage. This is where experts from across the financial world – including macro strategists, technical analysts, stock-pickers, and traders who specialize in options, currencies, and fixed income – come together to find the best ways to capitalize on recent developments in the market. Trading Nation: Where headlines become opportunities.

Michael Santoli

Michael Santoli joined CNBC in October 2015 as a Senior Markets Commentator, based at the network's Global Headquarters in Englewood Cliffs, N.J.  Santoli brings his extensive markets expertise to CNBC's Business Day programming, with a regular appearance on CNBC's “Closing Bell (M-F, 3PM-5PM ET).   In addition, he contributes to CNBCand CNBC PRO, writing regular articles and creating original digital videos.

Previously, Santoli was a Senior Columnist at Yahoo Finance, where he wrote analysis and commentary on the stock market, corporate news and the economy. He also appeared on Yahoo Finance video programs, where he offered insights on the most important business stories of the day, and was a regular contributor to CNBC and other networks.

Follow Michael Santoli on Twitter @michaelsantoli

Read more